Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EU 103

Next Previous
Drug Profile

EU 103

Alternative Names: Anti-VSIG4 antibody – Eutilex; EU-103

Latest Information Update: 29 Mar 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eutilex
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action CD4-positive T-lymphocyte stimulants; Complement receptor antagonists; Macrophage stimulants; Phosphorylation modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 02 Jun 2023 Pharmacodynamics data from a preclinical studies in Cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
  • 04 Apr 2023 Eutilex plans a phase I trial for Solid tumors (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in South Korea (IV, Infusion) in June 2023 (NCT05798026)
  • 20 Oct 2022 Preclinical trials in Cancer in South Korea (Parenteral) before October 2022 (Eutilex pipeline; October 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top